00:19 , Jul 12, 2019 |  BC Extra  |  Clinical News

Amyloid hypothesis takes first hit in an Alzheimer’s prevention setting

With Novartis and Amgen’s decision to halt a pair of trials in presymptomatic Alzheimer’s patients Thursday, what was widely considered the only setting left for the amyloid hypothesis in the disease took a blow. Amyloid-lowering...
01:17 , Jun 29, 2019 |  BC Extra  |  Company News

Management tracks: Carrick names Pearson CEO in U.S. push; plus AC Immune, Paratek and more

Cancer company Carrick Therapeutics Ltd. (Dublin, Ireland) hired Tim Pearson as CEO. He succeeds Elaine Sullivan, one of the company's founders, who will become executive entrepreneur and an adviser to the board. Pearson, who was...
00:42 , Jun 22, 2019 |  BioCentury  |  Product Development

Is tau the new amyloid?

After finally getting the message that they need to look beyond amyloid to treat Alzheimer’s disease, pharmas are lining up behind tau as the next big target. The question is whether they can pick out...
01:42 , May 4, 2019 |  BioCentury  |  Product Development

How the amyloid hypothesis holds its grip

By now, two things are clear about the amyloid hypothesis of Alzheimer’s disease: one is that the amyloid peptide is somehow involved; the other is that it’s a terrible target. β amyloid has had an...
01:39 , May 4, 2019 |  BioCentury  |  Product Development

Amyloid: how did we get here and what can we learn?

Unlike any other theory in drug development, the amyloid hypothesis of Alzheimer’s disease has maintained an almost cult-like following, despite two decades littered with a long line of late-stage failures and not a single success....
21:06 , Feb 28, 2019 |  BC Innovations  |  Tools & Techniques

Synuclein PET project

As the Parkinson’s field starts to solve the problem of how to detect toxic α-synuclein in the brain, it’s closing in on imaging agents that could de-risk clinical trials. Phase I data expected this year...
01:11 , Feb 1, 2019 |  BC Week In Review  |  Clinical News

Roche stops crenezumab trials in early Alzheimer's for futility

The β amyloid hypothesis for treating Alzheimer's disease suffered another setback on Jan. 30 after Roche (SIX:ROG; OTCQX:RHHBY) discontinued a pair of Phase III trials of crenezumab (RG7412) to treat early AD. Roche's Genentech Inc....
23:47 , Jan 30, 2019 |  BC Extra  |  Clinical News

Roche stops crenezumab trials in early Alzheimer’s for futility

The β amyloid hypothesis for treating Alzheimer's disease suffered another setback Wednesday after Roche (SIX:ROG; OTCQX:RHHBY) discontinued a pair of Phase III trials of crenezumab (RG7412) to treat early AD. Roche's Genentech Inc. unit has...
23:50 , Jan 3, 2019 |  BC Extra  |  Company News

Management tracks: Barrett joins UroGen

Uro-oncology company UroGen Pharma Ltd. (NASDAQ:URGN) named Elizabeth Barrett as president and CEO. She replaces Ron Bentsur. Last month, Barrett joined the exodus of pharma leaders heading to biotech as she departed Novartis AG (NYSE:NVS;...
19:22 , Dec 14, 2018 |  BC Week In Review  |  Company News

Lilly, AC Immune to develop tau inhibitors

Eli Lilly and Co. (NYSE:LLY) partnered with AC Immune S.A. (NASDAQ:ACIU) to develop the biotech's pipeline of tau aggregation inhibitors, dubbed Morphomers, to treat Alzheimer's disease. The deal includes AC Immune's lead candidate, ACI-3024, which...